Drug Trial Radar · NCT05610813
Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain
Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
384
Actual
Start
Jun 8, 2023
Primary completion
Oct 18, 2024
Study completion Oct 18, 2024
Sponsor
- Lead sponsor
- Vertanical GmbHIndustry
- Sponsor type
- Industry
- First posted
- Nov 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized, open-label, parallel-group phase III trial to prove an additional benefit of the full-spectrum cannabis extract VER-01 over opioids in patients with chronic non-specific low back pain for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.
Conditions
- Chronic Non-specific Low Back Pain
Interventions
VER-01Drug
Standardized oleoresin of Cannabis sativa L. folium cum flore, THC-chemotype (cannabis leaves and - flowers), corresponding to 21 mg (-)-trans-Δ9-Tetra-hydrocannabinol (THC) per gram drug product
Opioid therapyDrug
The patient-specific selection of the marketed opioid (based on standard of care and provided for this study) is at the discretion of the investigator and made at Visit 1, i.e., before randomization at Visit 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Risk of developing constipationTime frame: 190 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Rheumazentrum Prof. Dr. med. Gunther Neeck
Bad Doberan, Germany
Medizinische Hochschule Hannover (MHH)
Hanover, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.